


ABSTRACT OF THE DISCLOSURE

The invention relates to the use of derivatives of F-type
 5 prostaglandins as ocular hypotensives. The PGF derivatives used in
 accordance with the invention are represented by the following formula I:



wherein wavy line attachments indicate either the alpha (α) or beta (β)
 configuration; dashed bonds represent a double bond, or a single bond, R is a
 substituted heteroaryl radical, R^1 is hydrogen or a lower alkyl radical having
 up to six carbon atoms, X is selected from the group consisting of $-OR^1$,
 $-N(R^1)_2$, R^1 is hydrogen or a lower alkyl radical having up to six carbon
 atoms, X is selected from the group consisting of $-OR^1$, $-N(R^1)_2$ and $-$
 $N(R^5)SO_2R^6$, wherein R^5 represents hydrogen or CH_2OR^6 and R^6 represents
 hydrogen or a lower alkyl radical having up to six carbon atoms and halogen
 substituted derivatives of said lower alkyl radical, e.g. a fluoro substituted
 lower alkyl radical; Y is $=O$ or represents 2 hydrogen radicals. Certain of the
 compounds represented by Formula I comprise another aspect of the present
 invention.